Imatinib Recruiting Phase 2 Trials for Hypereosinophilic Syndromes Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00044304Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome